Stuart A. Arbuckle - 24 Feb 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, COO
Signature
/s/ Joy Liu, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
24 Feb 2023
Net transactions value
-$2,810,055
Form type
4
Filing time
28 Feb 2023, 15:47:58 UTC
Previous filing
24 Feb 2023
Next filing
04 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $1,362,912 -4,714 -7.1% $289.12 61,590 24 Feb 2023 Direct
transaction VRTX Common Stock Sale $1,100,971 -3,834 -6.2% $287.16 57,756 27 Feb 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $115,036 -400 -0.69% $287.59 57,356 27 Feb 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $231,136 -800 -1.4% $288.92 56,556 27 Feb 2023 Direct F1, F2, F5
holding VRTX Common Stock 140 24 Feb 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2 Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.16 (range $286.57 to $287.51).
F4 Open market sales reported on this line occurred at a weighted average price of $287.59 (range $287.57 to $287.60).
F5 Open market sales reported on this line occurred at a weighted average price of $288.92 (range $288.57 to $289.38).